根据克罗恩病患者的吸烟状况评估生物疗法的进展情况
Madeline Alizadeh1,2, Osman Ali2, Raymond K Cross2
1Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Inflammatory bowel diseases
|July 21, 2023
概括
吸烟不会影响克罗恩病 (CD) 患者的生物测序. 然而,由于已知的负面健康影响,建议患者戒烟至关重要.
科学领域:
- 胃肠病学 胃肠病学
- 炎症性肠病 (IBD) 的研究.
- 临床流行病学临床流行病学
背景情况:
- 活跃吸烟是克罗恩病 (CD) 发展和进展的已知危险因素.
- 患有CD的吸烟者面临较高的不良结果风险,增加治疗需求和复发风险.
- 吸烟对CD中的生物治疗序列的影响仍然不清楚.
研究的目的:
- 研究吸烟状况与克罗恩病患者使用的生物疗法数量之间的关联.
- 为了确定当前或前吸烟者与从未吸烟者相比是否需要更多的生物测序.
- 确定与CD中生物测序增加相关的潜在风险因素.
主要方法:
- 预期成人研究队列与IBD (SPARC IBD) 注册表研究的回顾性审查 (2016年12月 - 2021年1月).
- 对281名克罗恩病患者的分析,分为目前的,前的和从未吸烟的人.
- 通过使用的生物制剂数量 (0,1,或≥2) 来衡量结果.
主要成果:
- 目前的,前的和从未吸烟者之间没有观察到生物测序的统计学上显著差异.
- 增加生物测序的独立风险因素包括女性性别,结肠结肠疾病的位置,诊断时的年龄较小,疾病持续时间较长.
- 在经过调整后的分析中,这些风险因素并没有继续显著.
结论:
- 这是第一次研究吸烟与CD中的生物测序的关联.
- 虽然吸烟与生物测序的增加没有相关性,但它仍然是健康状况不佳的重要风险因素.
- 需要进一步的研究来根据烟草暴露水平分层风险,并加强对CD患者的戒烟咨询.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
174
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
174
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
153
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
153
Inflammatory Bowel Disease IV: Pharmacological Management
154
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
154
Inflammatory Bowel Disease II: Crohn's Disease
296
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
296
COPD: Management Using Bronchodilators and Corticosteroids
249
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
249


